BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Update

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 1,050,000 shares, a growth of 16.8% from the November 30th total of 898,700 shares. Based on an average daily volume of 613,300 shares, the short-interest ratio is presently 1.7 days.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BTAI. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of BioXcel Therapeutics in the second quarter valued at approximately $39,000. XTX Topco Ltd increased its position in shares of BioXcel Therapeutics by 49.0% during the 2nd quarter. XTX Topco Ltd now owns 46,503 shares of the company’s stock valued at $60,000 after purchasing an additional 15,291 shares during the last quarter. Finally, Armistice Capital LLC raised its stake in shares of BioXcel Therapeutics by 705.2% during the 2nd quarter. Armistice Capital LLC now owns 2,987,000 shares of the company’s stock worth $3,823,000 after purchasing an additional 2,616,027 shares during the period. 30.68% of the stock is currently owned by hedge funds and other institutional investors.

BioXcel Therapeutics Stock Up 1.9 %

NASDAQ BTAI traded up $0.01 on Tuesday, reaching $0.37. The company had a trading volume of 848,866 shares, compared to its average volume of 841,668. The stock has a market capitalization of $15.98 million, a P/E ratio of -0.17 and a beta of 0.11. The company’s fifty day moving average is $0.51 and its 200 day moving average is $0.72. BioXcel Therapeutics has a 52-week low of $0.30 and a 52-week high of $4.17.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their price objective on shares of BioXcel Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Monday, October 21st.

BioXcel Therapeutics Company Profile

BioXcel Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.